US biotech sector poised for 2026 rebound as IPO interest revives

By Sriparna Roy and Christy Santhosh Jan 14 (Reuters) - Investors are eyeing a rebound in the U.S. biotech sector in 2026, as more companies are expected to go public amid a renewed deal-making appetite and a lower interest rate scenario, even as they come ​to terms with the political and regulatory environment. Amid President Donald Trump's policy shifts, the most disruptive scenarios for healthcare now appear less ‌likely, helping restore a degree of confidence after tariff threats, funding cuts and s ...